MXC - MGC Pharmaceuticals' focus will not change despite psilocybin news
(NewsDirect)
MGC Pharmaceuticals Ltd (LSE:MXC,OTC:MGCLF, ASX:MXC) chief commercial officer Robert Clements speaks toProactive after announcing that the company has been grantedpermission by the Slovenian government to conduct research intopsilocybin, a naturally occurring psychedelic compound found incertain types of mushrooms.
Thecompany will work in partnership with other pharmaceutical companiesto determine the best potential use for psilocybin.
Clementssays that "the focus of MGC will not change" despite the news,adding that it is fully committed to its current pipeline ofproducts.
Contact Details
Proactive UKLtd
+44 20 7989 0813
Copyright (c) 2023 TheNewswire - All rights reserved.